Harold Eugene Brakewood net worth and biography

Harold Brakewood Biography and Net Worth

Insider of Immuneering

Harold E. Brakewood ("E.B.") has served as Immuneering's Chief Business Officer since March 2023.He joined Immuneering from Regeneron Pharmaceuticals where he most recently served as Vice President, Business Unit Head for oncology, Covid19, and new product planning. At Regeneron his teams launched three medicines in six indications in the U.S. and globally, including the anti-PD1 Libtayo for patients with advanced cancers. Prior to Regeneron, Mr. Brakewood held several positions of increasing responsibility over 20 years at Merck (MSD), including strategic planning during the launch of Keytruda, business development, brand management, and leadership of an oncology start-up venture. Mr. Brakewood received an MBA from Harvard Business School, an M.A. in physics from Dartmouth College and a B.A. in physics from Bowdoin College.

What is Harold Eugene Brakewood's net worth?: The estimated net worth of Harold Eugene Brakewood is at least $57.35 thousand as of January 16th, 2026. Mr. Brakewood owns 11,050 shares of Immuneering stock worth more than $57,350 as of May 6th. This net worth estimate does not reflect any other assets that Mr. Brakewood may own. Learn More about Harold Eugene Brakewood's net worth.
How do I contact Harold Eugene Brakewood?: The corporate mailing address for Mr. Brakewood and other Immuneering executives is , , . Immuneering can also be reached via phone at 617-500-8080 and via email at [email protected]. Learn More on Harold Eugene Brakewood's contact information.
Has Harold Eugene Brakewood been buying or selling shares of Immuneering?: Harold Eugene Brakewood has not been actively trading shares of Immuneering during the last quarter. Most recently, on Friday, January 16th, Harold Eugene Brakewood bought 5,250 shares of Immuneering stock. The stock was acquired at an average cost of $4.76 per share, with a total value of $24,990.00. Following the completion of the transaction, the insider now directly owns 11,050 shares of the company's stock, valued at $52,598. Learn More on Harold Eugene Brakewood's trading history.
Who are Immuneering's active insiders?: Immuneering's insider roster includes Harold Brakewood (Insider), Peter Feinberg (Director), Brett Hall (Chief Scientific Officer), Diana Hausman (Director), Leah Neufeld (Chief People Officer), Thomas Schall (Director), and Benjamin Zeskind (CEO). Learn More on Immuneering's active insiders.
Are insiders buying or selling shares of Immuneering?: In the last year, Immuneering insiders bought shares 21 times. They purchased a total of 200,126 shares worth more than $712,543.52. The most recent insider tranaction occured on January, 16th when insider Harold Eugene Brakewood bought 5,250 shares worth more than $24,990.00. Insiders at Immuneering own 22.9% of the company. Learn More about insider trades at Immuneering.
Information on this page was last updated on 1/16/2026.

Harold Eugene Brakewood Insider Trading History at Immuneering

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2026	Buy	5,250	$4.76	$24,990.00	11,050
6/20/2025	Buy	1,900	$2.53	$4,807.00	5,800
3/22/2024	Buy	3,900	$2.57	$10,023.00	3,900

Harold Eugene Brakewood Buying and Selling Activity at Immuneering

Immuneering Company Overview

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Today's Range

Now: $5.19

$5.06

$5.40

50 Day Range

MA: $5.32

$4.78

$6.13

2 Week Range

Now: $5.19

$1.10

$10.08

Volume

1,057,917 shs

Average Volume

1,392,805 shs

Market Capitalization

$335.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37